Content Outline 1. Nature of Antigen 2. Immunogenicity 3. Test Your Understanding 4. References & Further Reading

Total Page:16

File Type:pdf, Size:1020Kb

Load more

DEPARTMENT OF BIOTECHNOLOGY FACULTY OFENGINEERING & TECHNOLOGY LT.5 Nature of antigen, immunogenicity, antigenicity Content Outline 1. Nature of antigen 2. Immunogenicity 3. Test your understanding 4. References & Further reading LT.5 Nature of antigen Antigen is a substances usually protein in nature and sometimes polysaccharide, that generates a specific immune response and induces the formation of a specific antibody or specially sensitized T cells or both. An immunogen is any antigen that is capable of inducing humoral and/or cell-mediated immune response rather than immunological tolerance. This ability is called immunogenicity. Sometimes the term immunogen is used interchangeably with the term antigen. But only an immunogen can evoke an immune response. Antigen Vs Immunogen Immunogen is a stimulus that produces a humoral or cell-mediated immune response, whereas antigens are any substance that binds specifically to an antibody or a T-cell receptor. Epitope is immunologically active regions of an immunogen (or antigen) that binds to antigen- specific membrane receptors on lymphocytes or to secreted antibodies. It is also called antigenic determinants. Autoantigens, for example, are a person’s own self antigens. Examples: Thyroglobulin, DNA, Corneal tissue, etc. Alloantigens are antigens found in different members of the same species (the red blood cell antigens A and B are examples). Heterophile antigens are identical antigens found in the cells of different species. Examples: Forrssman antigen, Cross-reacting microbial antigens, etc. Adjuvants are substances that are non-immunogenic alone but enhance the immunogenicity of any added immunogen. Chemical Nature of Antigen Chemical Nature of Antigens (Immunogens) A. Proteins The vast majority of immunogens are proteins. These may be pure proteins or they may be glycoproteins or lipoproteins. In general, proteins are usually very good immunogens. B. Polysaccharides Pure polysaccharides and lipopolysaccharides are good immunogens. C. Nucleic Acids Nucleic acids are usually poorly immunogenic. However, they may become immunogenic when single stranded or when complexed with proteins. D. Lipids In general lipids are non-immunogenic, although they may be haptens. Types of Antigen Types of Antigen On the basis of order of their class (Origin) 1. Exogenous antigens These antigens enters the body or system and start circulating in the body fluids and trapped by the APCs (Antigen processing cells such as macrophages, dendritic cells, etc.) The uptakes of these exogenous antigens by APCs are mainly mediated by the phagocytosis Examples: bacteria, viruses, fungi etc Some antigens start out as exogenontigens, and later become endogenous (for example, intracellular viruses) 2. Endogenous antigens These are body’s own cells or sub fragments or compounds or the antigenic products that are produced. The endogenous antigens are processed by the macrophages which are later accepted by the cytotoxic T – cells. Endogenous antigens include xenogenic (heterologous), autologous and idiotypic or allogenic (homologous) antigens. Examples: Blood group antigens, HLA (Histocompatibility Leukocyte antigens), etc. 3. Autoantigens An autoantigen is usually a normal protein or complex of proteins (and sometimes DNA or RNA) that is recognized by the immune system of patients suffering from a specific autoimmune disease These antigens should not be, under normal conditions, the target of the immune system, but, due mainly to genetic and environmental factors, the normal immunological tolerance for such an antigen has been lost in these patients. Examples: Nucleoproteins, Nucleic acids, etc. On the basis of immune response 1. Complete Antigen or Immunogen Posses antigenic properties denovo, i.e. ther are able to generate an immune response by themselves. High molecular weight (more than 10,000) May be proteins or polysaccharides 2. Incomplete Antigen or Hapten •These are the foreign substance, usually non-protein substances •Unable to induce an immune response by itself, they require carrier molecule to act as a complete antigen. •The carrier molecule is a non-antigenic component and helps in provoking the immune response. Example: Serum Protein such as Albumin or Globulin. •Low Molecular Weight (Less than 10,000) •Haptens can react specifically with its corresponding antibody. •Examples: Capsular polysaccharide of pneumococcus, polysaccharide “C” of beta haemolytic streptococci, cardiolipin antigens, etc. Determinants of Antigenicity The whole antigen does not evoke immune response and only a small part of it induces B and T cell response. The small area of chemical grouping on the antigen molecule that determines specific immune response and reacts specifically with antibody is called an antigenic determinant. Property of antigens/ Factors Influencing Immunogenicity Immunogenicity is determined by: 1. Foreignness An antigen must be a foreign substances to the animal to elicit an immune response. 2. Molecular Size The most active immunogens tend to have a molecular mass of 14,000 to 6,00,000 Da. Examples: tetanus toxoid, egg albumin, thyroglobulin are highly antigenic. Insulin (5700 ) are either non-antigenic or weakly antigenic. 3. Chemical Nature and Composition •In general, the more complex the substance is chemically the more immunogenic it will be. •Antigens are mainly proteins and some are polysaccharides. •It is presumed that presence of an aromatic radical is essential for rigidity and antigenicity of a substance. 5. Antigen Specificity Antigen Specificity depends on the specific actives sites on the antigenic molecules (Antigenic determinants). Antigenic determinants or epitopes are the regions of antigen which specifically binds with the antibody molecule. 6. Species Specificity Tissues of all individuals in a particular species possess, species specific antigen. Human Blood proteins can be differentiated from animal protein by specific antigen-antibody reaction. 7. Organ Specificity •Organ specific antigens are confined to particular organ or tissue. •Certain proteins of brain, kidney, thyroglobulin and lens protein of one species share specificity with that of another species. 8. Auto-specificity The autologous or self antigens are ordinarily not immunogenic, but under certain circumstances lens protein, thyroglobulin and others may act as autoantigens. 9. Genetic Factors •Some substances are immunogenic in one species but not in another .Similarly, some substances are immunogenic in one individual but not in others (i.e. responders and non-responders). •The species or individuals may lack or have altered genes that code for the receptors for antigen on B cells and T cells. •They may not have the appropriate genes needed for the APC to present antigen to the helper T cells. 10. Age Age can also influence immunogenicity. Usually the very young and the very old have a diminished ability to elicit and immune response in response to an immunogen. 11. Degradability Antigens that are easily phagocytosed are generally more immunogenic. This is because for most antigens (T-dependant antigens) the development of an immune response requires that the antigen be phagocytosed, processed and presented to helper T cells by an antigen presenting cell (APC). 12. Dose of the antigen The dose of administration of an immunogen can influence its immunogenicity. There is a dose of antigen above or below which the immune response will not be optimal. 13. Route of Administration Generally the subcutaneous route is better than the intravenous or intragastric routes. The route of antigen administration can also alter the nature of the response. Antigen administered intravenously is carried first to the spleen, whereas antigen administered subcutaneously moves first to local lymph nodes. 14. Adjuvants Substances that can enhance the immune response to an immunogen are called adjuvants. The use of adjuvants, however, is often hampered by undesirable side effects such as fever and inflammation. Example: aluminum hydroxide. References & Further reading References 1. https://microbiologyinfo.com/antigen-properties-types-and-determinants-of-antigenicity/ 2. https://www.slideshare.net/yeyehsantos/nature-of-antigens?from_action=save Further reading 1. Kuby, RA Goldsby, Thomas J. Kindt, Barbara, A. Osborne Immunology, 6th Edition, Freeman, 2002. 2. Brostoff J, Seaddin JK, Male D, Roitt IM., Clinical Immunology, 6th Edition, Gower Medical Publishing, 2002. 3. Janeway et al., Immunobiology, 4th Edition, Current Biology publications. 1999. 4. Paul, Fundamental of Immunology, 4th edition, Lippencott Raven, 1999..
Recommended publications
  • Evaluation of T-Cell and B-Cell Epitopes and Design of Multivalent Vaccines Against Htlv-1 Diseases

    Evaluation of T-Cell and B-Cell Epitopes and Design of Multivalent Vaccines Against Htlv-1 Diseases

    EVALUATION OF T-CELL AND B-CELL EPITOPES AND DESIGN OF MULTIVALENT VACCINES AGAINST HTLV-1 DISEASES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Roshni Sundaram, M.S. * * * * * The Ohio State University 2003 Dissertation Committee: Approved by Professor Pravin T.P. Kaumaya, Adviser Professor Christopher M. Walker Adviser Professor Neil R. Baker Department of Microbiology Professor Marshall V. Williams ABSTRACT Human T-cell lymphotropic virus type I (HTLV-1) is a C type retrovirus that is the causative agent of an aggressive T-cell malignancy, adult T-cell leukemia/lymphoma (ATLL). The virus is also implicated in a number of inflammatory disorders, the most prominent among them being HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP). HTLV-1, like many viruses that cause chronic infection, has adapted to persist in the face of an active immune response in infected individuals. The viral transactivator Tax is the primary target of the cellular immune response and humoral responses are mainly directed against the envelope protein. Vaccination against HTLV-1 is a feasible option as there is very little genetic and antigenic variability. Vaccination regimes against chronic viruses must be aimed at augmenting the immune response to a level that is sufficient to clear the virus. This requires that the vaccine delivers a potent stimulus to the immune system that closely resembles natural infection to activate both the humoral arm and the cellular arm. It is also clear that multicomponent vaccines may be more beneficial in terms of increasing the breadth of the immune response as well as being applicable in an outbred population.
  • Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins

    Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins

    European Medicines Agency London, 13 December 2007 Doc. Ref. EMEA/CHMP/BMWP/14327/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS DRAFT AGREED BY BMWP July 2006 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION January 2007 END OF CONSULTATION (DEADLINE FOR COMMENTS) July 2007 AGREED BY BMWP October 2007 ADOPTION BY CHMP December 2007 DATE FOR COMING INTO EFFECT April 2008 KEYWORDS Immunogenicity, unwanted immune response, biotechnology derived proteins, immunogenicity risk factors, assays, clinical efficacy and safety, risk management 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS TABLE OF CONTENTS EXECUTIVE SUMMARY................................................................................................................... 3 1. INTRODUCTION......................................................................................................................... 3 2. SCOPE............................................................................................................................................ 4 3. LEGAL BASIS .............................................................................................................................
  • Risk Assessment and Mitigation Strategies for Immune Responses to Therapeutic Proteins: the FDA Perspective

    Risk Assessment and Mitigation Strategies for Immune Responses to Therapeutic Proteins: the FDA Perspective

    Risk Assessment and Mitigation Strategies for Immune Responses to Therapeutic Proteins: the FDA Perspective Amy S. Rosenberg, M.D. Supervisory Medical Officer, Office of Biotechnology Products CDER, FDA Risk is a Specific Knowledge Set Encompassing Both Consequences and Probabilities (modified from Stirling and Gee 2002) Knowledge about Consequences Knowledge about likelihoods Consequences Consequences well-defined poorly-defined Some basis Ambiguity Risk (I) for (III) probabilities Incertitude No basis for Uncertainty Ignorance probabilities (II) (IV) “Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products” U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2014 Clinical/Medical 3 Immunogenicity Risk Assessment: Consequences for Safety • Fatality/Severe Morbidity – Anaphylaxis: clinical definition, does not imply mechanism • Proteins of non-human origin, eg, aprotinin, asparaginase • Replacement human proteins in knock out phenotype: eg, Factor IX in hemophilia B – Cross reactive neutralization of endogenous factor or receptor homolog with unique function resulting in deficiency syndrome or cytokine release syndrome – Immune complex disease and delayed hypersensitivity • Serum sickness; nephropathy • Most often seen when high doses of therapeutic proteins are administered in setting of a sustained high titered antibody response Immunogenicity Risk Assessment Consequences for Efficacy
  • Monoclonal Antibody to Macrophages (Haematopoiesis Associated) - FITC

    Monoclonal Antibody to Macrophages (Haematopoiesis Associated) - FITC

    OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] BM4022F Monoclonal Antibody to Macrophages (Haematopoiesis associated) - FITC Alternate names: Macrophage marker Quantity: 0.2 mg Concentration: 0.4 mg/ml Background: 25F9 is associated with well-differentiated tissue macrophages both in normal and diseased tissues independently of the presence or absence of inflammation. The antigen is a 86kDa membrane protein, the epitope has not been further characterized. Host / Isotype: Mouse / IgG1 Recommended Isotype SM10F (for use in human samples) Controls: Clone: 25F9 Immunogen: Cultured human monocytes. Format: State: Liquid purified Ig fraction. Purification: Affinity chromatography. Buffer System: PBS buffer pH 7.2 with 0.09% sodium azide as preservative and 10 mg/ml BSA as stabilizer. Label: FITC Applications: Has been described to work in FACS. Antigen Distribution on Isolated cells and Tissue sections: Absent on freshly isolated monocytes and other blood cells; present on 40 - 50% of human monocytes after 6-7 day culture, also positive on some melanoma and carcinoma cell lines. Kupffer cells, histiocytes (skin), macrophages of the thymus, in the germinal centres of lymph nodes and spleen, in mamma carcinoma, melanoma, osteocarcinoma and gastric cancer; excema, sarcoidosis, BCG granuloma; synovial lining cells, tuberculoid leprosy: no expression in lepramatous leprosy. Other markers also used in the above studies include RM3/1, 27E10, G16/1, S36.48 and 8-5C2 in various combinations.
  • Measuring the Immunogenicity of Allogeneic Adult Mesenchymal Stem Cells Alix K

    Measuring the Immunogenicity of Allogeneic Adult Mesenchymal Stem Cells Alix K

    Berglund et al. Stem Cell Research & Therapy (2017) 8:288 DOI 10.1186/s13287-017-0742-8 REVIEW Open Access Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells Alix K. Berglund1*, Lisa A. Fortier2, Douglas F. Antczak3 and Lauren V. Schnabel1* Abstract Background: Autologous and allogeneic adult mesenchymal stem/stromal cells (MSCs) are increasingly being investigated for treating a wide range of clinical diseases. Allogeneic MSCs are especially attractive due to their potential to provide immediate care at the time of tissue injury or disease diagnosis. The prevailing dogma has been that allogeneic MSCs are immune privileged, but there have been very few studies that control for matched or mismatched major histocompatibility complex (MHC) molecule expression and that examine immunogenicity in vivo. Studies that control for MHC expression have reported both cell-mediated and humoral immune responses to MHC-mismatched MSCs. The clinical implications of immune responses to MHC-mismatched MSCs are still unknown. Pre-clinical and clinical studies that document the MHC haplotype of donors and recipients and measure immune responses following MSC treatment are necessary to answer this critical question. Conclusions: This review details what is currently known about the immunogenicity of allogeneic MSCs and suggests contemporary assays that could be utilized in future studies to appropriately identify and measure immune responses to MHC-mismatched MSCs. Keywords: Mesenchymal stem cell, Allogeneic, Immunogenicity, Major histocompatibility complex, Mixed leukocyte reaction, Cytotoxicity, ELISPOT, Microcytotoxicity Background in vivo [9], questioning the relevance of differentiation Mesenchymal stem cells (MSCs) are currently defined as to the therapeutic properties of MSCs when injected in a plastic-adherent cells with a fibroblast-like morphology naive state.
  • Difference Between Antigen and Immunogen What Is an Antigen?

    Difference Between Antigen and Immunogen What Is an Antigen?

    Difference Between Antigen and Immunogen www.differencebetween.com Key Difference - Antigen vs Immunogen Immunology is a branch of medicine and biology and is concerned about all aspects of the immune system in organisms. This is a much studied as it is vital to identify and assess the manner in which an organism protects itself against a foreign invasion. An immunological response is initiated upon the entry of a foreign entity which results in a cascade of reactions downstream to degrade or eliminate the foreign entity. An antigen is a foreign body or a molecule, which has the ability to bind to the antibody produced by the host in response to the recognition of the antigen. An immunogen is also a foreign molecule which can elicit an immune response by triggering the host immune system. The key difference between the antigen and the immunogen is their ability and the inability to generate an immune response;an immunogen is necessarily an antigen, but an antigen may not necessarily be an immunogen. What is an Antigen? Antigens are small molecular recognition sites present in the cellular surface of many bacteria, fungi, viruses, dust particles and other cellular and noncellular particles. These small molecules referred to as antigens,and they can be recognized by the host immune system. Antigens are mainly composed of proteins, amino acids, lipids, glycolipids, glycoproteins or nucleic acid markers. These molecules possess the ability to bind to the antibodies (immunoglobulins produced by B cells) produced by the host as an immune response. Antigens are also capable of triggering the host immune system to initiate an immune mechanism.
  • Size, Affinity, and Immunogenicity Peptide-Binding Repertoires Of

    Size, Affinity, and Immunogenicity Peptide-Binding Repertoires Of

    HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity This information is current as Sinu Paul, Daniela Weiskopf, Michael A. Angelo, John of September 29, 2021. Sidney, Bjoern Peters and Alessandro Sette J Immunol 2013; 191:5831-5839; Prepublished online 4 November 2013; doi: 10.4049/jimmunol.1302101 http://www.jimmunol.org/content/191/12/5831 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/11/05/jimmunol.130210 Material 1.DC1 http://www.jimmunol.org/ References This article cites 51 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/191/12/5831.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 29, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity Sinu Paul,1 Daniela Weiskopf,1 Michael A.
  • Immunogenicity Assessment of Therapeutic Proteins

    Immunogenicity Assessment of Therapeutic Proteins

    European Medicines Agency London, 24 January 2007 Doc. Ref. EMEA/CHMP/BMWP/14327/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS DRAFT AGREED BY BMWP July 2006 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION 24 January 2007 END OF CONSULTATION (DEADLINE FOR COMMENTS) 31 July 2007 Comments should be provided electronically in word format using this template to: [email protected] KEYWORDS Immunogenicity, biotechnology derived proteins, antigenicity risk factors, assays, clinical efficacy 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS TABLE OF CONTENTS EXECUTIVE SUMMARY................................................................................................................... 3 1. INTRODUCTION......................................................................................................................... 3 2. SCOPE............................................................................................................................................ 3 3. LEGAL BASIS .............................................................................................................................
  • Immune Escape Mechanisms As a Guide for Cancer Immunotherapy Gregory L

    Immune Escape Mechanisms As a Guide for Cancer Immunotherapy Gregory L

    Published OnlineFirst December 12, 2014; DOI: 10.1158/1078-0432.CCR-14-1860 Perspectives Clinical Cancer Research Immune Escape Mechanisms as a Guide for Cancer Immunotherapy Gregory L. Beatty and Whitney L. Gladney Abstract Immunotherapy has demonstrated impressive outcomes for exploited by cancer and present strategies for applying this some patients with cancer. However, selecting patients who are knowledge to improving the efficacy of cancer immunotherapy. most likely to respond to immunotherapy remains a clinical Clin Cancer Res; 21(4); 1–6. Ó2014 AACR. challenge. Here, we discuss immune escape mechanisms Introduction fore, promote tumor outgrowth. In this process termed "cancer immunoediting," cancer clones evolve to avoid immune-medi- The immune system is a critical regulator of tumor biology with ated elimination by leukocytes that have antitumor properties the capacity to support or inhibit tumor development, growth, (6). However, some tumors may also escape elimination by invasion, and metastasis. Strategies designed to harness the recruiting immunosuppressive leukocytes, which orchestrate a immune system are the focus of several recent promising thera- microenvironment that spoils the productivity of an antitumor peutic approaches for patients with cancer. For example, adoptive immune response (7). Thus, although the immune system can be T-cell therapy has produced impressive remissions in patients harnessed, in some cases, for its antitumor potential, clinically with advanced malignancies (1). In addition, therapeutic mono- relevant tumors appear to be marked by an immune system that clonal antibodies designed to disrupt inhibitory signals received actively selects for poorly immunogenic tumor clones and/or by T cells through the cytotoxic T-lymphocyte–associated antigen establishes a microenvironment that suppresses productive anti- 4 (CTLA-4; also known as CD152) and programmed cell death-1 tumor immunity (Fig.
  • Vaccine Immunology Claire-Anne Siegrist

    Vaccine Immunology Claire-Anne Siegrist

    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
  • Immunogen Design

    Immunogen Design

    applications and troubleshooting appendix chapter 21 Immunogen Design Antigens Used for Antibody Production • You can use synthetic peptides, recombinant proteins, immunogens, and others. We do not recommend the use of whole cells for anti- body production. • Arbitrary selection of the antigenic peptide or use of a recombinant fusion protein usually will result in a 65-70% success rate using standard methodologies. If the antigenic peptide is chosen using standard bioinformatic algorithms, you can increase your success rate to 75-80%. If this optimized peptide is then conjugated using Invitrogen’s proprietary approach, you can increase your success rate to about 85-90%. A recent collaborative study showed that approximately 450 polyclonal peptide antibodies out of 500 individual protein targets recognized their target by western blot analysis. Peptide Conjugation • Peptides are normally too short to be immunogenic. A carrier protein enhances immunogenicity. MAP and KLH are the two most popular conjugation methods. Other available conjugates are OVA (Ovalbumin), BSA (Bovine Serum Albumin), and THY (Thyroglobulin). • Conjugation is usually done through the sulfhydryl group of a Cys designed into the peptide. • For peptides < 6 kDa, conjugation will be required. • If studying invertebrate species, you should use carrier proteins such as ovalbumin and KLH (from sea snail). KLH has no homology to 21.2 vertebrate proteins. Invitrogen utilizes a proprietary multiple conjugation method where we conjugate peptides through both termini and through key internal sites. This methodology presents the peptides in alternate, multiple conformations, making them more antigenic and producing antibodies appendix with greater utility across assays. Our conjugation scheme provides a better matching of epitopes between the presented peptide and the way the peptides are presented in the native protein.
  • I M M U N O L O G Y Core Notes

    I M M U N O L O G Y Core Notes

    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111